Our blog

With AstraZeneca on its heels, J&J, AbbVie's Imbruvica speeds toward new nod in Waldenström's

admin 26th June 2018 Uncategorised 0

Johnson & Johnson and AbbVie’s Imbruvica is the only treatment approved for patients with the rare blood lymphoma Waldenström’s macroglobulinemia. But before competition arrives from AstraZeneca, the companies are pushing to widen that market.

More: With AstraZeneca on its heels, J&J, AbbVie's Imbruvica speeds toward new nod in Waldenström's
Source: fierce

FAQ’s

Our Clients

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Pellentesque sit amet libero magna. Mauris at enim vel nibh scelerisque porttitor id ut leo. Phasellus pretium, leo a lobortis aliquam, nunc tortor pulvinar ipsum, et vulputate lacus tortor a eros. Morbi consequat velit eget augue porttitor vitae molestie diam rutrum.

Management

. Phasellus porta ultrices ante at facilisis. Fusce ornare turpis sit amet lacus egestas elementum. Curabitur risus nunc, consequat ac euismod at, rhoncus in diam. Duis vel rhoncus eros. Phasellus ut neque nec tellus fringilla viverra. Donec pellentesque lectus a quam blandit dictum iaculis mauris ultricies. Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Community

Vestibulum ut nunc eu neque mollis accumsan. Fusce est ante, ultrices sed rutrum et, dictum ac nulla. Maecenas posuere bibendum fermentum. Donec iaculis, urna quis pellentesque rhoncus, justo est iaculis diam, pulvinar congue est tellus vel metus. Donec aliquet facilisis sapien. Donec tempor hendrerit purus a dapibus. Praesent aliquet leo ante. Donec non leo lacus, vitae venenatis augue. Vestibulum quam augue, congue a consectetur sed, eleifend a mi.

M	T	W	T	F	S	S
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30

Our blog

With AstraZeneca on its heels, J&J, AbbVie's Imbruvica speeds toward new nod in Waldenström's

Categories

Lorem ipsum

FAQ’s

Our Clients

Management

Community

Archive

Calendar